MA39088B1 - Compositions et procédés pour moduler des récepteurs farnesoïde x - Google Patents

Compositions et procédés pour moduler des récepteurs farnesoïde x

Info

Publication number
MA39088B1
MA39088B1 MA39088A MA39088A MA39088B1 MA 39088 B1 MA39088 B1 MA 39088B1 MA 39088 A MA39088 A MA 39088A MA 39088 A MA39088 A MA 39088A MA 39088 B1 MA39088 B1 MA 39088B1
Authority
MA
Morocco
Prior art keywords
compositions
receptors
methods
farnesoid
modulating farnesoid
Prior art date
Application number
MA39088A
Other languages
English (en)
French (fr)
Other versions
MA39088A1 (fr
Inventor
Valentina Molteni
Donatella Chianelli
Xiaodong Liu
John Nelson
Jason Roland
Paul Rucker
David Tully
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51982773&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA39088(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA39088A1 publication Critical patent/MA39088A1/fr
Publication of MA39088B1 publication Critical patent/MA39088B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
MA39088A 2013-11-05 2014-11-04 Compositions et procédés pour moduler des récepteurs farnesoïde x MA39088B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361900013P 2013-11-05 2013-11-05
PCT/US2014/063948 WO2015069666A1 (en) 2013-11-05 2014-11-04 Compositions and methods for modulating farnesoid x receptors

Publications (2)

Publication Number Publication Date
MA39088A1 MA39088A1 (fr) 2017-07-31
MA39088B1 true MA39088B1 (fr) 2018-06-29

Family

ID=51982773

Family Applications (1)

Application Number Title Priority Date Filing Date
MA39088A MA39088B1 (fr) 2013-11-05 2014-11-04 Compositions et procédés pour moduler des récepteurs farnesoïde x

Country Status (42)

Country Link
US (5) US9682939B2 (OSRAM)
EP (1) EP3065738B1 (OSRAM)
JP (1) JP6424231B2 (OSRAM)
KR (1) KR102350357B1 (OSRAM)
CN (1) CN105682656B (OSRAM)
AP (1) AP2016009165A0 (OSRAM)
AR (1) AR098316A1 (OSRAM)
AU (1) AU2014346919B2 (OSRAM)
BR (1) BR112016009630B1 (OSRAM)
CA (1) CA2927705C (OSRAM)
CL (1) CL2016000982A1 (OSRAM)
CR (1) CR20160212A (OSRAM)
CU (1) CU24375B1 (OSRAM)
CY (1) CY1120273T1 (OSRAM)
DK (1) DK3065738T3 (OSRAM)
EA (1) EA030430B1 (OSRAM)
ES (1) ES2670984T3 (OSRAM)
GT (1) GT201600085A (OSRAM)
HR (1) HRP20180817T1 (OSRAM)
HU (1) HUE039155T2 (OSRAM)
IL (1) IL245242B (OSRAM)
JO (1) JO3454B1 (OSRAM)
LT (1) LT3065738T (OSRAM)
MA (1) MA39088B1 (OSRAM)
MX (1) MX364834B (OSRAM)
MY (1) MY175903A (OSRAM)
NO (1) NO3105103T3 (OSRAM)
NZ (1) NZ719078A (OSRAM)
PE (1) PE20160682A1 (OSRAM)
PH (1) PH12016500777B1 (OSRAM)
PL (1) PL3065738T3 (OSRAM)
PT (1) PT3065738T (OSRAM)
RS (1) RS57179B1 (OSRAM)
SG (1) SG11201603026PA (OSRAM)
SI (1) SI3065738T1 (OSRAM)
SV (1) SV2016005192A (OSRAM)
TN (1) TN2016000143A1 (OSRAM)
TR (1) TR201807321T4 (OSRAM)
TW (1) TWI662027B (OSRAM)
UY (1) UY35818A (OSRAM)
WO (1) WO2015069666A1 (OSRAM)
ZA (1) ZA201602555B (OSRAM)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2545964A1 (en) 2011-07-13 2013-01-16 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
MX364834B (es) 2013-11-05 2019-05-08 Novartis Ag Composiciones y metodos para modular los receptores x farnesoides.
TWI698430B (zh) 2015-02-13 2020-07-11 南北兄弟藥業投資有限公司 三環化合物及其在藥物中的應用
EP3288948B1 (en) * 2015-04-30 2019-11-20 Novartis AG Fused tricyclic pyrazole derivatives useful for modulating farnesoid x receptors
CN108697702A (zh) 2016-02-22 2018-10-23 诺华股份有限公司 使用fxr激动剂的方法
SI3730487T1 (sl) 2016-06-13 2022-08-31 Gilead Sciences, Inc. Azetidinski derivati kot modulatorji FXR (NR1H4)
CA3252823A1 (en) 2016-06-13 2025-02-25 Gilead Sciences Inc Fxr (nr1h4) modulating compounds
KR102205368B1 (ko) * 2016-09-14 2021-01-20 노파르티스 아게 Fxr 작용제의 신규 요법
JOP20190040A1 (ar) * 2016-09-14 2019-03-10 Novartis Ag توليفة من ناهضات fxr
JP2019530696A (ja) * 2016-10-05 2019-10-24 ノバルティス アーゲー 線維性、硬変性の疾患もしくは障害を治療または予防するためのｆｘｒアゴニストを含む組合せ組成物
CN107973790A (zh) * 2016-10-22 2018-05-01 合帕吉恩治疗公司 杂环fxr调节剂
JP6906626B2 (ja) 2017-03-28 2021-07-21 ギリアード サイエンシーズ， インコーポレイテッド 肝疾患を処置するための治療的組み合わせ
IL271035B (en) * 2017-06-05 2022-09-01 Nat Univ Singapore Compounds useful in inhibiting human trefoil factor 3
WO2019034693A1 (en) 2017-08-15 2019-02-21 Inflazome Limited SULFONYLURATES AND SULFONYLTHIOURES AS INHIBITORS OF NLRP3
JP2020531453A (ja) 2017-08-15 2020-11-05 インフレイゾーム リミテッド Ｎｌｒｐ３阻害剤としてのスルホニルウレアおよびスルホニルチオウレア
WO2019034692A1 (en) 2017-08-15 2019-02-21 Inflazome Limited SULFONYLURATES AND SULFONYLTHIOURES AS INHIBITORS OF NLRP3
US20200276178A1 (en) * 2017-09-13 2020-09-03 Novartis Ag Combinations comprising fxr agonists
US12221434B2 (en) 2017-11-09 2025-02-11 Inflazome Limited Sulfonamide carboxamide compounds
JP2021502364A (ja) 2017-11-09 2021-01-28 インフレイゾーム リミテッド 新規なスルホンアミドカルボキサミド化合物
CN110128432B (zh) * 2018-02-02 2021-03-02 广东东阳光药业有限公司 含氮三环化合物及其在药物中的应用
WO2019166619A1 (en) 2018-03-02 2019-09-06 Inflazome Limited Novel compounds
CN112424207B (zh) 2018-07-25 2024-03-19 诺华股份有限公司 Nlrp3炎性小体抑制剂
US11225473B2 (en) 2019-01-15 2022-01-18 Gilead Sciences, Inc. FXR (NR1H4) modulating compounds
US10610280B1 (en) 2019-02-02 2020-04-07 Ayad K. M. Agha Surgical method and apparatus for destruction and removal of intraperitoneal, visceral, and subcutaneous fat
EP3927683A1 (en) 2019-02-19 2021-12-29 Gilead Sciences, Inc. Solid forms of fxr agonists
UY38687A (es) 2019-05-17 2023-05-15 Novartis Ag Inhibidores del inflamasoma nlrp3, composiciones, combinaciones de los mismos y métodos para su uso
WO2021009332A1 (en) 2019-07-18 2021-01-21 Enyo Pharma Method for decreasing adverse-effects of interferon
WO2021044351A1 (en) 2019-09-06 2021-03-11 Novartis Ag Methods of treating liver disease using lta4h inhibitors
CA3159163A1 (en) 2020-01-15 2021-07-22 Raphael Darteil Use of fxr agonists for treating an infection by hepatitis d virus
CN113387828A (zh) * 2020-03-14 2021-09-14 江巨东 一种阿利克仑中间体的制备方法
WO2022037663A1 (zh) * 2020-08-21 2022-02-24 苏州晶云药物科技股份有限公司 苯甲酸衍生物的新晶型及其制备方法
CA3204800A1 (en) 2021-01-14 2022-07-21 Raphael Darteil Synergistic effect of a fxr agonist and ifn for the treatment of hbv infection
US20240216364A1 (en) 2021-04-28 2024-07-04 Enyo Pharma Strong potentiation of tlr3 agonists effects using fxr agonists as a combined treatment
UY40374A (es) 2022-08-03 2024-02-15 Novartis Ag Inhibidores de inflamasoma nlrp3
WO2024044778A2 (en) * 2022-08-26 2024-02-29 Celmatix Inc. Novel modulators of fshr and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050143449A1 (en) * 2002-11-15 2005-06-30 The Salk Institute For Biological Studies Non-steroidal farnesoid X receptor modulators and methods for the use thereof
US7846960B2 (en) * 2006-05-24 2010-12-07 Eli Lilly And Company FXR agonists
BRPI0716901B1 (pt) * 2006-09-15 2020-04-22 Thales Avionics Inc sistema para transferir conteúdo e método para entregar conteúdo entre um veículo e outra entidade
TW200906823A (en) * 2007-07-16 2009-02-16 Lilly Co Eli Compounds and methods for modulating FXR
CU24152B1 (es) * 2010-12-20 2016-02-29 Irm Llc 1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr
MX364834B (es) 2013-11-05 2019-05-08 Novartis Ag Composiciones y metodos para modular los receptores x farnesoides.
EP3288948B1 (en) 2015-04-30 2019-11-20 Novartis AG Fused tricyclic pyrazole derivatives useful for modulating farnesoid x receptors

Also Published As

Publication number Publication date
TR201807321T4 (tr) 2018-06-21
PH12016500777A1 (en) 2016-05-30
WO2015069666A1 (en) 2015-05-14
LT3065738T (lt) 2018-05-10
ES2670984T3 (es) 2018-06-04
EA030430B1 (ru) 2018-08-31
CU20160063A7 (es) 2016-09-30
PH12016500777B1 (en) 2016-05-30
US20170275256A1 (en) 2017-09-28
NZ719078A (en) 2018-07-27
AR098316A1 (es) 2016-05-26
BR112016009630A8 (pt) 2020-04-07
US9682939B2 (en) 2017-06-20
BR112016009630B1 (pt) 2021-02-09
KR20160079091A (ko) 2016-07-05
US20200247757A1 (en) 2020-08-06
HRP20180817T1 (hr) 2018-06-29
UY35818A (es) 2015-05-29
CL2016000982A1 (es) 2016-10-07
TN2016000143A1 (en) 2017-10-06
PL3065738T3 (pl) 2018-07-31
EA201690930A1 (ru) 2016-08-31
SV2016005192A (es) 2016-11-21
RS57179B1 (sr) 2018-07-31
SG11201603026PA (en) 2016-05-30
CR20160212A (es) 2016-07-22
IL245242A0 (en) 2016-06-30
JO3454B1 (ar) 2020-07-05
MX364834B (es) 2019-05-08
PE20160682A1 (es) 2016-07-23
AU2014346919A1 (en) 2016-05-12
ZA201602555B (en) 2017-06-28
AU2014346919B2 (en) 2017-02-02
CY1120273T1 (el) 2019-07-10
TWI662027B (zh) 2019-06-11
PT3065738T (pt) 2018-06-04
MX2016005865A (es) 2016-07-13
US20160340317A1 (en) 2016-11-24
CA2927705A1 (en) 2015-05-14
US10077240B2 (en) 2018-09-18
US11021446B2 (en) 2021-06-01
MA39088A1 (fr) 2017-07-31
HUE039155T2 (hu) 2018-12-28
DK3065738T3 (en) 2018-06-06
CU24375B1 (es) 2018-12-05
JP6424231B2 (ja) 2018-11-14
TW201612163A (en) 2016-04-01
US10683271B2 (en) 2020-06-16
EP3065738A1 (en) 2016-09-14
SI3065738T1 (en) 2018-06-29
US20190062283A1 (en) 2019-02-28
US20210253534A1 (en) 2021-08-19
AP2016009165A0 (en) 2016-04-30
NO3105103T3 (OSRAM) 2018-05-12
KR102350357B1 (ko) 2022-01-14
IL245242B (en) 2019-03-31
CN105682656A (zh) 2016-06-15
GT201600085A (es) 2019-07-19
MY175903A (en) 2020-07-15
CN105682656B (zh) 2019-11-05
EP3065738B1 (en) 2018-02-28
JP2016535784A (ja) 2016-11-17
CA2927705C (en) 2021-09-21

Similar Documents

Publication Publication Date Title
MA39088A1 (fr) Compositions et procédés pour moduler des récepteurs farnesoïde x
MA34767B1 (fr) Compositions et procédés pour la modulation de fxr
EA201891799A1 (ru) Замещенные 1,2,3-триазолы в качестве nr2b-селективных модуляторов nmda
MA35753B1 (fr) Aryl-dihydropyridinones et pipéridinones en tant qu'inhibiteurs de mgat2
PH12018500777A1 (en) Farnesoid x receptor modulators
EA201390947A1 (ru) Соединения 2-амино-4-арилтиазола в качестве антагонистов trpa1
MA42410A (fr) Oxystérols et leurs méthodes d'utilisation
EA201491607A1 (ru) Модуляторы толлподобных рецепторов
MA39427A1 (fr) Composés pyrrolidine modulateurs de gpr40 pour le traitement de maladies telles que le diabète
MA42397B1 (fr) 4-azaindoles substituées et leur utilisation comme modulatoeurs de la récepteur glun2b
MY195888A (en) N-Substituted Indole Derivatives As Pge2 Receptor Modulators
MA35716B1 (fr) Formulations pharmaceutiques
MA41988B1 (fr) Azabenzimidazoles et leur utilisation comme modulateurs du recepteur ampa
EA201700504A1 (ru) 5-ароматическое алкинилзамещенное бензомидное соединение и способ его получения, фармацевтическая композиция и их применение
BR112015010779A2 (pt) moduladores de di-hidropirazol gpr40
EA201891267A1 (ru) Фармацевтическая композиция, содержащая действенный ингибитор urat1
BR112015010791A2 (pt) moduladores de gpr40 de di-hidropirazol
EA201992679A1 (ru) N-замещенные индольные производные
MA34805B1 (fr) Dérivés de 4-(5-cyano-pyrazole-1-yl)-pipéridine en tant que modulateurs du gpr119
MX2020007731A (es) Compuestos moduladores de receptor de estrogeno.
EA201591795A1 (ru) Бицикло[2.2.1]-кислоты в качестве модуляторов рецептора gpr120
MA43913B1 (fr) Modulateurs allostériques positifs du récepteur m1 muscarinique
MX393789B (es) Moduladores de los receptores a3 de adenosina
WO2015138276A3 (en) Retinoic acid receptor-related orphan receptor modulators and uses thereof
ZA202109194B (en) A substituted tetrahydroisoquinoline derivative as a d1 positive allosteric modulator